The 13th annual ADMET conference is returning to London, UK for an in-depth exploration of the optimisation of ADMET modelling techniques, preclinical DMPK applications and the development of bioph
Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA.
